Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma, Kaposi 1Sarcoma 1Osteosarcoma 1Multi-centric Castleman's Disease 1Melanoma 1Castleman Disease 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bone Neoplasms 1Acquired Immunodeficiency Syndrome 1

Interventions

Zidovudine 10Doxorubicin 10Vincristine 7Bleomycin 7Liposomes 5Interferon alpha-2 5tecogalan 4Etoposide 3sargramostim 2pomalidomide 2liposomal doxorubicin 2interferon alfa-n1 2Valganciclovir 2Ritonavir 2Paclitaxel 2Nivolumab 2Mitoxantrone 2Didanosine 2vesnarinone 1tocilizumab 1tin etiopurpurin 1abemaciclib 1Zalcitabine 1Tumor Necrosis Factor-alpha 1Sorafenib 1Semaxinib 1Ro 24-7429 1O-(Chloroacetylcarbamoyl)fumagillol 1Nevirapine 1Muromonab-CD3 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Acquired Immunodeficiency Syndrome × tocilizumab × Sarcoma × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡